middle.news

Memphasys Advances Felix™ CE Mark, Boosts Sales in Japan, Validates RoXsta™ Assay

2:45pm on Wednesday 30th of July, 2025 AEST Biotechnology
Read Story

Memphasys Advances Felix™ CE Mark, Boosts Sales in Japan, Validates RoXsta™ Assay

2:45pm on Wednesday 30th of July, 2025 AEST
Key Points
  • CE Mark submission for Felix™ completed; approval expected within 6–12 months
  • Direct sales launched in Japan, New Zealand, UAE, and Canada with repeat sales in Japan
  • RoXsta™ Mega Cell assay validated for high-throughput fertility and veterinary testing
  • $1.275 million capital raise supports regulatory filings and commercial expansion
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Memphasys (ASX:MEM)
OPEN ARTICLE